Alzheimer’s Disease Science
Halia’s Approach to Alzheimer’s Disease with HT-4253
HT-4253: Targeting LRRK2 in Alzheimer’s Disease
The Role of LRRK2 in Alzheimer’s Pathogenesis
Alzheimer’s disease (AD) is characterized by cognitive decline, amyloid-beta (Aβ) plaques, and tau tangles.4 HT-4253, an investigational LRRK2 inhibitor, is being developed by Halia Therapeutics to modulate Rab10 signaling, which is implicated in AD pathology.5 Preliminary research suggests that Rab10 may contribute to the spread of neurofibrillary tangles.6,7 However, this is based on early-stage research and requires clinical investigation.Investigational Status: HT-4253 is investigational and has not been approved for any indication. Statements about its potential effects on Alzheimer’s disease outcomes are based on preclinical studies, and clinical research is required to confirm its safety and efficacy in patients. Halia is conducting an ongoing phase 1 clinical trial to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of HT-4253 in healthy adults.Obesity
Almost half of US adults are obese or severely obese. Lack of physical activity, unhealthy eating behavior, and, in some cases, genetics contribute to obesity. Halia is developing investigational treatments to combat obesity.
Pain and Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune condition where the immune system—normally the body's defender against infection and disease—attacks its own tissues. This results in pain, swelling, stiffness, and loss of joint function. Halia is developing an investigational treatment for both RA and post-surgical pain.
Alzheimer's Disease
Alzheimer’s disease involves parts of the brain that control memory, language, problem-solving, and other thinking abilities. It can seriously affect a person’s ability to carry out daily activities. Halia is developing a potentially relevant pathway and investigational treatment for Alzheimer’s.
Parkinson's Disease
Parkinson’s disease is a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves. Tremors, stiffness, or slowing of movement are typical symptoms. Halia is developing a potential brain-penetrant compound to treat the disease.